| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Descriptive Information Fields | |||||
| Brief Title † | The Use of Repetitive Magnetic Stimulation for Strength Training of the Quadriceps Muscle | ||||
| Official Title † | The Use of Repetitive Magnetic Stimulation for Strength Training of the Quadriceps Muscle in Patients With Chronic Obstructive Pulmonary Disease | ||||
| Brief Summary | We intend to use repetitive magnetic stimulation to the quadriceps muscle to try to improve strength and improve the metabolic function of the muscle. |
||||
| Detailed Description | Quadriceps strength is reduced in COPD. Increasing quadriceps strength is one of the goals of pulmonary rehabilitation yet some patients with severe COPD are unable to exercise with sufficient intensity, due to breathlessness, to achieve a true training benefit. Transcutaneous electrical stimulation of the femoral nerve has been shown to improve quadriceps muscle strength, muscle mass, and performance in patients with severe COPD. Magnetic stimulation may be preferred because it offers the opportunity to train the whole muscle and because it is painless. In this pilot study we are investigating whether repetitive magnetic stimulation camn increase the strength of the quadriceps muscle and whether it confers any change in structure or metabolism of the muscle itself. |
||||
| Study Phase | |||||
| Study Type † | Interventional | ||||
| Study Design † | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study | ||||
| Primary Outcome Measure † | Quadriceps Twitch force | ||||
| Secondary Outcome Measure † | Quadriceps maximal voluntary contraction, Oxidative enzyme profile, fibre type distribution and capillarity of the muscle, quality of life questionnaires | ||||
| Condition † | Chronic Obstructive Pulmonary Disease | ||||
| Intervention † | Device: Repetitive magnetic stimulation to the quadriceps | ||||
| MEDLINE PMIDs | |||||
| Links | |||||
| Recruitment Information Fields | |||||
| Recruitment Status † | Completed | ||||
| Enrollment † | 20 | ||||
| Start Date † | January 2005 | ||||
| Completion Date | February 2006 | ||||
| Eligibility Criteria † | Inclusion Criteria: Chronic Obstructive Pulmonary Disease Exclusion Criteria: Aspirin therapy Cardiac Pacemaker - |
||||
| Gender | Both | ||||
| Ages | 40 Years to 85 Years | ||||
| Accepts Healthy Volunteers | No | ||||
| Contacts †† | |||||
| Location Countries † | United Kingdom | ||||
| Administrative Information Fields | |||||
| NCT ID † | NCT00159367 | ||||
| Organization ID | RR1 | ||||
| Secondary IDs †† | EU QLRT-2001-2285 | ||||
| Study Sponsor † | Imperial College London | ||||
| Collaborators †† | Magstim Company, Whitland, Wales | ||||
| Investigators † |
|
||||
| Information Provided By | Imperial College London | ||||
| Verification Date | August 2008 | ||||
| First Received Date † | September 9, 2005 | ||||
| Last Updated Date | August 18, 2008 | ||||
|
